Bradbury, Penelope A.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Pooled analysis of the prognostic and predictive value of KRAS mutation status and mutation subtype in patients with non-small cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors

Zer, A., Ding, K., Lee, S. M., Goss, G. D., Seymour, L., Ellis, P. M., Hackshaw, A., Bradbury, P. A., Han, L., O’Callaghan, C. J., et al. (2016) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 56

Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC

Cheng, M. L., Lau, C. J., Milan, M. S. D., Supplee, J. G., Riess, J. W., Bradbury, P. A., Jänne, P. A., Oxnard, G. R., & Paweletz, C. P. (2021) · JCO Precision Oncology

Lung Cancer Treatments and MutationsCancer Genomics and Diagnostics

Cited by 29

Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non–small-cell Lung Cancer

Tomasini, P., Mascaux, C., Jao, K., Labbe, C., Kamel-Reid, S., Stockley, T., Hwang, D. M., Leighl, N. B., Liu, G., Bradbury, P. A., et al. (2019) · Clinical Lung Cancer

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 22